Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
US10869868B2 · kind B2 · utility
2Cited by
6References
13Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 26, 2017 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Jan 26, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.